European Commission Approves Henlius and Organon’s Biosimilars for Bone Disorders
SHANGHAI, China & JERSEY CITY, NJ – September 19, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN)...
Bio-Pharma
Advertisement
TREMFYA® Receives FDA Approval for Subcutaneous Induction in UC
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
Monte Rosa and Novartis Expand Degrader Alliance in Immunology
BOSTON, Mass., September 15, 2025 – Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company pioneering molecular glue...
FDA Approves LEQEMBI IQLIK Subcutaneous Autoinjector for Maintenance Dosing in Early Alzheimer’s Disease
Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...
GeneseeqPrime Gains FDA 510(k) Clearance for Tumor Profiling Kit
TORONTO, Sept. 2, 2025 – Geneseeq Technology Inc. announced that its GeneseeqPrime® NGS Tumor Profiling Assay has received 510(k)...
Advertisement
